Clinical Trial Update: A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy [Phase 2]

View source ↗

Summary

A Phase II double-blind study evaluating delavirdine mesylate in combination with AZT and/or ddI versus AZT/ddI therapy for HIV infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• AZT (Zidovudine) (Zidovudine)
• Delavirdine mesylate (U-90152) (delavirdine)
• didanosine (ddI) (didanosine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED